Stem Cells Therapy in Degenerative Diseases of the Retina

Status Enrolling by invitation

Clinical Trial Summary

The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells administered intravitreously in the subjects with degenerative diseases of the retina.

Clinical Trial Description

Degenerative diseases of the retina are challenging for ophthalmologists. This is a common term that covers heterogenous group of diseases, f.e. retinitis pigmentosa, Stargardt disease, Best's disease or age related macular degeneration. Undetermined etiology, wide range of factors that may trigger the onset of the disease and modulate it's course impede the implementation of an effective treatment. Currently, a stem cells therapy seems to be promising option in patients with degenerative diseases of the retina. The purpose of this prospective, nonrandomized, open label, pilot study is to conduct the investigation of the safety and efficacy of intravitreal injection of autologous bone marrow-isolated stem/progenitor cells with different selected phenotypes into the subjects with degenerative diseases of the retina. Especially, this clinical trial is designated to test the therapeutic (pro-regenerative and neuro-protective) functions of different stem/progenitor cell populations able to secrete bioactive neurotrophic factors. All patients enrolled will have a documented history of degenerative disease of the retina prior to study enrollment. Next, autologous bone marrow-isolated stem/progenitor cells intravitreous injection will be performed. Finally, treatment safety, adverse events and exploratory parameters, including best corrected visual acuity, visual field and electroretinography parameters, to establish disease progression rate will be recorded throughout the duration of the post-treatment follow up period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03772938
Study type	Interventional
Source	Pomeranian Medical University Szczecin
Contact
Status	Enrolling by invitation
Phase	Phase 1
Start date	December 13, 2018
Completion date	March 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01432847` - Cell Collection to Study Eye Diseases
Completed	`NCT04983914` - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting	`NCT03845218` - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed	`NCT00231010` - Molecular Genetics of Retinal Degenerations
Active, not recruiting	`NCT04611503` - PDE6A Gene Therapy for Retinitis Pigmentosa	Phase 1/Phase 2
Completed	`NCT02909985` - Visual Activity Evoked by Infrared in Humans After Dark Adaptation	N/A
Recruiting	`NCT01914913` - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa	Phase 1/Phase 2
Completed	`NCT01949623` - Biomarkers In Retinitis Pigmentosa (BIRP)	N/A
Completed	`NCT01835002` - Transcorneal Electrical Stimulation - Multicenter Safety Study	N/A
Completed	`NCT00407602` - Argus® II Retinal Stimulation System Feasibility Protocol	N/A
Completed	`NCT00515814` - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors	N/A
Completed	`NCT00100230` - DHA and X-Linked Retinitis Pigmentosa	Phase 2
Active, not recruiting	`NCT00378742` - Repository for Inherited Eye Diseases
Terminated	`NCT05085964` - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa	Phase 2
Recruiting	`NCT05805007` - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa	Early Phase 1
Recruiting	`NCT06291935` - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene	Phase 1
Recruiting	`NCT05909488` - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II	Phase 2/Phase 3
Recruiting	`NCT03078309` - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients	Early Phase 1
Completed	`NCT04238858` - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa	N/A
Active, not recruiting	`NCT01680510` - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil	Phase 1/Phase 2